Advances in the management of TTP
M Subhan, M Scully - Blood reviews, 2022 - Elsevier
Thrombotic thrombocytopenic purpura is an acute life-threatening disorder, associated with
a mortality of 90% if unrecognised and untreated. The hallmark is thrombocytopenia and …
a mortality of 90% if unrecognised and untreated. The hallmark is thrombocytopenia and …
Emerging concepts in immune thrombotic thrombocytopenic purpura
A Laghmouchi, NAG Graça, J Voorberg - Frontiers in immunology, 2021 - frontiersin.org
Immune thrombotic thrombocytopenic purpura (iTTP) is an autoimmune disorder of which
the etiology is not fully understood. Autoantibodies targeting ADAMTS13 in iTTP patients …
the etiology is not fully understood. Autoantibodies targeting ADAMTS13 in iTTP patients …
Plasma cell directed therapy for immune thrombotic thrombocytopenic purpura (iTTP)
M Chen, J Shortt - Transfusion Medicine Reviews, 2022 - Elsevier
Immune thrombotic thrombocytopenic purpura (iTTP) is a microangiopathic hemolytic
anemia (MAHA) underpinned by autoreactivity against the von Willebrand factor (vWF) …
anemia (MAHA) underpinned by autoreactivity against the von Willebrand factor (vWF) …
Bortezomib in relapsed/refractory immune thrombotic thrombocytopenic purpura: A single‐centre retrospective cohort and systematic literature review
Immune thrombotic thrombocytopenic purpura (iTTP) is a rare and life‐threatening
haematological condition. Initial treatment involves plasma exchange (PLEX) …
haematological condition. Initial treatment involves plasma exchange (PLEX) …
Bortezomib, a promising alternative for patients with refractory or relapsed thrombotic thrombocytopenic purpura after rituximab treatment.
J Yin, H Tian, D Kong, Y Li, C Gu… - British Journal of …, 2022 - search.ebscohost.com
Patriquin et al. 10 treated six refractory iTTP patients with bortezomib, except for one case
died in the treatment, all the other 5 patients remained in remission after a mean follow-up of …
died in the treatment, all the other 5 patients remained in remission after a mean follow-up of …
Kaposi's sarcoma, biologics and small molecules: Navigating the complex interplay between host immunity and viral biology. A case series with focused review of the …
L Brambilla, CA Maronese, E Zelin… - Dermatologic …, 2022 - Wiley Online Library
The consequences of cytokine‐specific immune modulation in the development and course
of Kaposi's sarcoma (KS) are poorly understood. A retrospective chart review of patients …
of Kaposi's sarcoma (KS) are poorly understood. A retrospective chart review of patients …
[HTML][HTML] 硼替佐米、 糖皮质激素为基础的联合方案治疗6 例复发/难治免疫性血栓性血小板减少性紫癜
殷杰， 田竑， 孔丹青， 李云， 顾骋圆… - Chinese Journal of …, 2023 - ncbi.nlm.nih.gov
硼替佐米、糖皮质激素为基础的联合方案治疗6例复发/难治免疫性血栓性血小板减少性紫癜-
PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI …
PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI …
[引用][C] Plasma cell‐directed therapy strategies in immune‐mediated thrombotic thrombocytopenic purpura (iTTP)
P Patır, N Önkibar, S Subari, AE Eşkazan - Transfusion, 2024 - Wiley Online Library
Immune-mediated thrombotic thrombocytopenic purpura (iTTP) occurs due to an acquired
deficiency of ADAMTS13, a metalloprotease necessary for cleaving ultra-large von …
deficiency of ADAMTS13, a metalloprotease necessary for cleaving ultra-large von …